Progenity Inc. (NASDAQ: PROG) has shared two poster presentations presented at the 17th Congress of the European Crohns and Colitis Organisation on February 18, 2022.
Progenity presents posters on ulcerative colitis
Dr. Geert D’Haens and Mr. Joep van Oostrom presented a poster entitled “Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe UC,” which looked into the reasons for the 30% of patients who do not react to anti-TNF medications. Interleukin 6 (IL6), a pro-inflammatory cytokine seen at elevated amounts in tissue, could be a trigger of inflammation in ulcerative colitis instead of TNF. This shows that a combination of treatments is required.
Dr. Séverine Vermeire and Dr. Bram Verstockt presented a poster titled “Tofacitinib tissue exposure correlates with endoscopic outcome,” which showed a link between mucosal visibility and endoscopic betterment in tofacitinib-treated ulcerative colitis populations with medium to severe ulcerative colitis
CEO Adi Mohanty stated, “Many ulcerative colitis patients go through several rounds of treatment with various drugs and see no improvement. These are people who are suffering. By establishing data on the amount of mucosal exposure needed to achieve clinical outcomes, and also achieving a better understanding of the multiple inflammatory pathways that contribute toward the pathophysiology of ulcerative colitis, the independent research presented by our collaborators at ECCO helps to establish the foundation for two areas of opportunity to improve outcomes for patients with UC.”
Progenity’s targeted therapies tech offers enhanced dosages and addresses toxicity.
The company’s targeted therapies technology is built to provide greater dosages in tissue while addressing the toxicity issues associated with systemic absorption. Reduced systemic absorption could pave the way for combination treatment that targets different inflammatory processes at the same time, the company’s technology will open up new avenues for potential therapy combinations for individuals who are now unable to attain symptom remission.
The DDS targeted therapies platform employs a unique strategy that maximizes the possible dose at the location of disease while lowering systemic toxicity, potentially improving IBD patient outcomes.
